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Abstract
Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) have been widely used for the
treatment of non-small cell lung cancer (NSCLC). KRAS and EGFR somatic mutations in NSCLC may predict
resistance and responsiveness to TKI, respectively. Nevertheless, most research to date has been conducted on
samples from primary tumors. For many patients with advanced disease, their samples can only be obtained from
metastases for test. The molecular characteristics of metastasized tumors may be different from those of primary
tumors.
Materials and methods: Mutation status of KRAS and EGFR between primary tumors and local lymph node
metastases of 80 Chinese patients with NSCLC were analyzed by direct sequencing. Five of them were given
gefitinib as neoadjunvant treatment after the EGFR-TKI sensitive mutations were detected in their biopsies of
mediastinal lymph nodes metastases. McNemar’s test was used to compare the EGFR and KRAS mutation status
between primary tumors and corresponding local lymph node metastases. Data evaluation was carried out with
SPSS_13.0 statistical software.
Results: Among the 160 samples, one primary tumor and seven metastases were identified with KRAS mutations
and 21 primary tumors and 26 metastases were found to have EGFR mutations. KRAS and EGFR mutation status
was different between primary tumors and corresponding metastases in 6 (7.5%) and 7 (8.75%) patients,
respectively. One patient with no TKI sensitive mutations detected in the primary tumor showed disease
progression.
Conclusion: Our results suggest that a considerable proportion of NSCLC in Chinese population showed
discrepancy in KRAS and EGFR mutation status between primary tumors and corresponding metastases. This
observation may have important implication for the use of targeted TKI therapy in the treatment of NSCLC
patients.
Introduction
Lung cancer is one of the leading causes of cancer-
related mortality both in China and throughout the
world [1,2]. Non-small cell lung cancer (NSCLC)
accounts for75-80% of all lung cancer [3]. Standard
therapeutic strategies such as surgery, chemotherapy, or
radiotherapy have reached a plateau [1]. Significant
advances in the research of the biology and molecular
mechanisms of cancer have allowed the development of
new molecularly targeted agents for the treatment of
NSCLC [4-8]. One such target is the epidermal growth
factor receptor (EGFR), a 170-kDa trans-membrane gly-
coprotein and member of erbB family. Small molecule
tyrosine kinase inhibitors (TKI), such as gefitinib and
erlotinib, disrupt EGFR kinase activity by binding the
adenosine triphosphate pocket within the catalytic
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any medium, provided the original work is properly cited.region of the tyrosine kinase domain [9]. Currently, both
gefitinib and erlotinib are used for treatment of patients
with advanced NSCLC. TKI clinical trials have shown
that these agents have dramatic effect on the subset of
NSCLC patients with somatic mutations in the tyrosine
kinase domain of the EGFR gene, whereas the presence
of KRAS mutations seems to be correlated with primary
resistance to these agents [10-15]. So it is necessary to
identify the mutation status of KRAS and EGFR for
selection of patients who are more likely to benefit from
TKI. Although almost 70% of patients with NSCLC pre-
sent with locally advanced or metastatic disease at the
time of diagnosis [16,17], KRAS and EGFR mutation sta-
tus is most commonly assessed only in the primary
tumor tissue based on the assumption that primary and
metastases are pathologically concordant. However, it
has been known that lung cancers are often heteroge-
neous at the molecular level even within the same
tumor and many key molecular alterations may occur
during metastatic progression [18-20]. It is still unclear
whether KRAS and EGFR mutation status in primary
tumors is reflected in their corresponding metastases in
Chinese patients with NSCLC, although several recent
relevant studies in western countries have been per-
formed and published [21-26].
In the present study, we investigate KRAS and EGFR
mutation status using PCR-based sequencing analyses in
80 primary tumor samples and their corresponding local
lymph node metastases from Chinese patients with
NSCLC. The goal is to determine whether KRAS and
EGFR mutation profile is stable during the metastatic
progress and to investigate the clinical usefulness of
mutational analyses in primary tumor versus in metas-
tases for planning EGFR-targeted therapies for the treat-
ment of patients with NSCLC.
Materials and methods
Patients and samples
Patients were selected from a pathological database of
lung cancer cases undergoing curative resection for
excision of primary tumor and the corresponding
lymph nodes metastases at the Pathology Department
of Tianjin Medical University Cancer Hospital from
March 2009 to September 2009. Only patients with
paraffin embedded tissues from surgically resected pri-
mary lung cancers and lung cancer-related local
lymph node metastatic samples with histologically
confirmed NSCLC were included. Patients who had
been exposed to TKI before surgical treatment were
excluded from this study. In each case, hematoxylin
and eosin-stained sections of formalin-fixed paraffin-
embedded tissue of primary tumor and corresponding
synchronous lymph node metastases were reviewed by
two pathologists to identify neoplastic areas and the
amount of tumor cells in order to ensure that they
contained more than 70% of tumor components for
DNA extraction and mutation analysis. Tissue blocks
were macro-dissected using a safety blade when sam-
ples were less than 70% of tumor cells. Primary tumor
and lymph node specimens were obtained from all
patients by surgical resection of primary tumors with
lymph nodes dissection according to prevailing surgi-
cal standards. Consequently, 80 pairs of primary
tumors and the corresponding lymph nodes metas-
tases were analyzed. All samples were from patients of
Chinese origin with NSCLC. The characteristics of the
included patients were shown in Table 1.
The inclusive criteria for selecting patients to receive
gefitinib as neoadjunvant therapy were as follows: (1)
NSCLC verified by cytology or histology; (2) age 18 to
70 years; (3) NSCLC with stage ⅢAo rⅢBa n dt h e
tumors were confined in homolateral thoracic cavity; (4)
patients without metastases in contralateral mediastinal
lymph node; (5) patients who have never received treat-
ment; (6) patients who could tolerate the surgery; (7)
patients who were willing to receive preoperative target
therapy. The exclusive criteria were: (1) without definite
diagnosis; (2) age ≥ 70 years; (3) NSCLC with N3 or dis-
tant metastases; (4) small cell lung cancer; (5) patients
who have been treated before; (6) patients who were
unable to tolerate radical surgery. The local ethics com-
mittee granted approval, and written informed consent
was obtained from each patient.
DNA extraction
Thirty mg of frozen tissue was shredded by scissors. The
E.Z.N.ATM Tissue DNA Kit (purchased by OMEGA)
was used to extract genomic DNA. Quality and concen-
tration of the DNA samples were examined by Nano
Drop (Thermo™). Genomic DNA was then diluted to a
working concentration of 5-10 ng/ul.
Table 1 Patients’ Characteristics (N = 80)
Characteristics Patient Number (%)
Age, mean (range) 58 (32-77)
Gender
Male 50 (62.5)
Female 30 (37.5)
Pathologic type
Adenocarcinoma 39 (48.75)
Squamous cell carcinoma 31 (38.75)
Adenosquamous carcinoma 6 (7.5)
Large cell carcinoma 4 (5)
Smoking history
Ever 49 (61.25)
Never 31 (38.75)
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The two codons of KRAS (12 and 13) and two exons of
EGFR (19 and 21) were amplified by PCR using the fol-
lowing forward and reverse primers: exon 1 of KRAS:5 ’-
AAAGGTACTGGTGGAGTATTTGATAGTG-3’,5‘
-TCATGAAAATGGTCAGAGAAACCT- 3 ‘; EGFR ex
on19 :5‘ -AGCATGTGGCACCATCTCAC-3’,5’-
GCAGGGTCTAGAGCAGAGCAG-3’; EGFRexon
21 :5‘ -CTGAATTCGGATGCAGAGC
TT-3‘,5‘ -CTAGTGGGAAGGCAGCC
TGGT-3 .At o t a lo f2 0μl PCR reaction system
included the following: 1x HotStarTaq buffer, 2.0 mM
Mg2+, 0.2 mM dNTP, 0.2 μM of each primer, 1U Hot-
StarTaq Polymerase (Qiagen), and 10ng DNA template.
PCR reaction procedures were performed using 35
cycles of 15 sec at 94°C, 30 sec at 56°C, 1 min at 72°C
and extension for 2 min at 72°C. Sequencing reactions
were performed on an ABI3700 genetic analyzer after
PCR products were purified. Sequence variations were
determined using Seqscape software (Applied Biosys-
tems) with the KRAS and EGFR reference sequence
(NM_004985 and NM_005228.3, National Center for
Biotechnology Information).
In order to avoid contamination during PCR steps,
gloves and lab coats were worn at all times when PCR is
performed. Pipette tips with aerosol filters were used to
prevent microdroplets being injected into the PCR mix-
ture. DNA sample preparation was done in a separate
room from the area where PCR reaction mixes were
prepared. Additionally negative control was also
included during PCR procedure.
Drug administration
Five patients received gefitinib as first-line treatment
after being identified to harbor EGFR-TKI sensitive
mutations in mediastinal lymph nodes metastases
obtained by mediastinoscope. One tablet of gefitinib
(250 mg) was taken once daily at about the same time.
Patients continued the course uninterrupted until dis-
ease progression, intolerable toxicity or withdrawal of
consent. All drugs were supplied by AstroZeneca.
Assessment of response
Baseline evaluation included medical history and physi-
cal examination, electrocardiogram, chest radiography,
thorax CT scan and ultrasonography of the upper abdo-
men. Laboratory investigations included complete blood
counts, urinalysis, renal function and liver function tests.
Performance status was evaluated according to the East-
ern Cooperative Oncology Group (ECOG) criteria.
Patients were re-evaluated, using the same method at
the end of the first and third months of therapy, and
then every 3 months. Objective tumor response and its
duration were assessed according to the RECIST criteria
[27], and all responses were confirmed >28 days after
the initial assessment of response.
Statistical analysis
McNemar’s test was used to compare the EGFR and
KRAS mutation status between primary tumors and cor-
responding local lymph node metastases. Two-sided p
values <0.05 were considered significant. Data evaluation
was carried out with SPSS_13.0 statistical software.
Results
KRAS gene mutations in NSCLC primary tumors and
corresponding local lymph node metastases
KRAS mutations were detected in one primary tumor
and seven lymph node metastases (Table 2). All of them
were point mutations: five in codon 12 (G12A, G12V,
G12S), two in codon 13 (G13D). Only one patient car-
ried the same KRAS mutation in both primary tumor
and metastatic tumor (Table 2, case 31). Six samples
had mutations in lymph node metastases but not in
their corresponding primary tumor tissues (Table 2,
case7 to case12). Two of the KRAS mutation-positive
samples (Table 2, case 7 and case 8) also carried the
L858R EGFR mutation. NSCLC samples harboring both
KRAS and EGFR mutations have rarely been reported
previously. One sample had a KRAS mutation only in
the metastases; the other one had KRAS mutations in
both sites. The correlation between KRAS mutation and
clinical parameters such as gender, smoke history and
pathologic type was not statistically significant. Discor-
dance in KRAS mutation status between primary tumors
and lymph node metastases observed in six patients was
found statistically significant (McNemar’st e s t ,P =
0.0412, Table 3). The majority (6/7) of all cases with
KRAS mutations were squamous cell lung cancers. The
other one was an adenocarcinoma.
EGFR gene mutations in NSCLC primary tumors and
corresponding local lymph node metastases
EGFR mutations were detected in twenty-one primary
tumors and twenty-six lymph node metastases. The
types and locations of the mutations in paired tumors
were shown in Table 2. Thirteen cases of the in-frame
deletions in exon 19 and eight cases of point mutation
in exon 21 were found in the primary tumors. Twenty-
six cases with EGFR mutations in the lymph nodes
included fourteen cases of the in-frame deletions in
exon 19 and twelve cases of the point mutation in exon
21. All point mutations found in those samples were
Leucin to Arginine at position 858 (L858R). The clinico-
pathologic characteristics that were significantly asso-
ciated with EGFR mutations were gender, smoke history
and pathologic type. Woman, non-smoker and adeno-
carcinoma showed a higher percentage of EGFR
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Discordant cases included five cases with no EGFR
mutation in the primary tumors (Table 2, cases 3 to 7)
and two cases with the metastases having a different
EGFR mutation (Table 2, case 1 and case 2) (McNe-
mar’s test, P = 0.0736, Table 3).
Response to gefitinib as neoadjuvant treatment
Five patients (Table 2, case 3 and cases 20 to 23) were
given gefitinib as neoadjunvant treatment after the
EGFR-TKI sensitive mutations were detected in their
biopsies of mediastinal lymph nodes metastases by DNA
direct sequencing. Of the five patients, three harbored
delE746-A750 in exon 19 and the other two harbored
L858R in exon 21. Four patients showed response to
gefitinib and one experienced progressive disease.
Among the four patients showing response to gefitinib,
the size of both primary tumors and the mediastinal
lymph nodes were found to shrink when examined by
thorax CT scan (Figure 1). All four patients responded
to gefitinib then received radical resection of the pul-
monary carcinomas successfully after being evaluated to
be suitable for surgery. Then their primary tumors har-
vested from surgery were examined for the EGFR muta-
tions. We found that all four samples had the same
mutations as those found in their mediastinal lymph
nodes metastases. The patient who experienced progres-
sive disease on gefitinib showed volume increase of the
primary tumor and obvious hydrothorax, not a candi-
date for surgery according to NCCN Guidelines™ (Fig-
ure 2). With permission of this patient, we obtained his
primary tumor tissue through ultrasound-guided aspira-
tion in order to examine the gene mutation status. No
mutations were detected in either the EGFR gene or the
KRAS gene in the primary tumor from this patient.
Discussion
NSCLC represents a major global health problem, but
the introduction of a novel class of targeted anti-neo-
plastic agents, EGFR TKI, directed against EGFR has
significantly changed the therapeutic options available
for patients with NSCLC. Several studies have shown
that activating EGFR mutations in exon 18, 19 and 21
are associated with a 75-95% objective response rate
with EGFR TKI, whereas KRAS mutations are associated
with a lack of sensitivity to these agents. However, of all
patients with newly diagnosed NSCLC, 65-75% has
advanced and unresectable disease. Up to half of
patients with NSCLC develop metastases at the time of
the initial diagnosis, and more patients eventually
experience metastases in the course of their disease.
KRAS and EGFR mutation status has been analyzed in
primary tumors in the majority of the current studies,
but it has been demonstrated that lung cancers are
Table 2 Comparison of EGFR and KRAS status between
primary and metastatic tumors in NSCLC patients
Case No. EGFR mutation status KRAS mutation status
primary metastasis primary metastasis
1 E746-A750 L747-T751 wt wt
2 L747-P753insS R748-P752 wt wt
3 wt L747-P753 wt wt
4 wt L858R wt wt
5 wt L858R wt wt
6 wt L858R wt wt
7 wt L858R wt G12V
8 L858R L858R wt G12A
9 wt wt wt G12V
10 wt wt wt G13D
11 wt wt wt G12S
12 wt wt wt G13D
13 E746-A750 E746-A750 wt wt
14 E746-A750 E746-A750 wt wt
15 E746-A750 E746-A750 wt wt
16 E746-A750 E746-A750 wt wt
17 E746-A750 E746-A750 wt wt
18 E746-A750 E746-A750 wt wt
19 E746-A750 E746-A750 wt wt
20 L858R L858R wt wt
21 L858R L858R wt wt
22 L858R L858R wt wt
23 L858R L858R wt wt
24 L858R L858R wt wt
25 L858R L858R wt wt
26 L858R L858R wt wt
27 L747-S752,P753E L747-S752,P753E wt wt
28 E746-T751insV/A E746-T751insV/A wt wt
29 E747-S752insV E747-S752insV wt wt
30 I740-K745 I740-K745 wt wt
31 wt wt G12A G12A
32 wt wt wt wt
.
.
.
80 wt wt wt wt
Table 3 Combined analysis of EGFR and KRAS status in
NSCLC patients
Primary/Metastatic tumor
WT/WT WT/MUT MUT/WT MUT/MUT Discordance
EGFR 54 5 0 21* 7 case
KRAS 73 6 0 1 6 case
* E746-A750/L747-T751; L747-P753insS/R748-P752.
Abbreviation: WT, wild type; MUT, mutational type.
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the same tumor. In addition, molecular characteristics
may differ between primary tumor and metastases. The
classical model for metastatic process suggests that most
cells of a given primary tumor have low metastatic
potential and only a few cells acquire enough somatic
mutations to become metastatic [28]. Consequently, it is
of primary importance to verify the degree of correlation
between primary tumor and corresponding metastases
with regard to KRAS and EGFR mutation status in order
to select patients who will be most likely to benefit from
the treatment with TKI.
In this study we assessed KRAS and EGFR mutation
status in 80 pairs of NSCLC primary tumors and their
corresponding local lymph node metastases to evaluate
whether KRAS and EGFR mutation status changed dur-
ing disease progression. We found that tumors metasta-
sized to the lymph nodes did not always show the same
gene status as their primary compartments. In our
study, the discordance in KRAS and EGFR gene status
was 7.5% (6/80) and 8.75% (7/80), respectively. To our
knowledge, there have been several recent similar stu-
dies in western countries. For example, Kalikaki et al.
reported that the discordance in KRAS and EGFR gene
status between primary tumors and corresponding
metastases was 24% and 28% in 25 patients with
NSCLC, respectively [24]. Schmid et al. reported that
the KRAS and EGFR gene status in primary tumors and
Figure 1 Case 21 showed that the sizes of both the primary tumor and the mediastinal lymph nodes were found to shrink after
gefitinib therapy when examined by thorax CT scan.
Figure 2 Case 3 showed volume increase of primary tumor and obvious hydrothorax after gefitinib therapy, as determined by thorax
CT scan.
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(6.25%) patients among 96 patients, respectively [26].
Monaco et al. compared 40 pairs of primary lung tumors
with their metastases and found nine cases (22.5%) with a
discordant KRAS status [21]. More recently, Cortot et al.
performed mutant-enriched PCR (ME-PCR) to analyze
KRAS gene status in primary tumors and their matched
metastases. They found that the use of ME-PCR allowed a
resolution of the discordance in 3 of the 6 cases by
demonstrating the presence of low levels of mutant KRAS
in lesions that were found negative by direct sequencing.
Their data suggests that some gene discordance could be
resolved by using techniques with increased sensitivity and
that highly sensitive tools are required to identify biomar-
kers [29]. The difference between our findings with low
discordant rate and those earlier studies might be due to
different ethnic background of the patients studied. In
western countries, KRAS mutation rate is high in NSCLC
patients, especially in those with adenocarcinoma (30%-
50%), but EGFR mutation rate is low (3%-8%). However,
Asian patients with NSCLC harbor more EGFR mutations
(30%-60%) and fewer KRAS mutation (4%-24%) than wes-
tern patients [30-37]. Given that there are obvious genetic
differences between somatic mutations in KRAS and
EGFR genes in patients from Asia and western countries,
it is very likely that changes of the mutation status during
disease progression are different. Because relevant data
about Chinese or Asian was not searched, further study
should be performed to disclose the molecular
mechanism.
Majority of the discordant cases in our study showed
KRAS and EGFR mutations in the metastatic tumors
rather than in their corresponding primary tumors
(Table 2). This result suggests that the gene mutation
status may change during metastases after diagnosis of
the primary tumors. Although the molecular basis for
this disparity is unclear, this information still has poten-
tial important clinical implications. This biological phe-
nomenon of discordant gene mutations could partially
account for the fact that some advanced NSCLC
patients with apparent wild-type EGFR respond to
EGFR TKI and other patients with well-known EGFR
TKI-sensitive mutations in their primary tumors failed
to respond to EGFR TKI. It is interesting that in our
study we observed one case with delL747-P753 in med-
iastinal lymph nodes metastases showing progressive
disease after gefitinib therapy. No EGFR mutation was
found in its paired primary tumor. To our knowledge,
this is the first study of the relationship between gene
mutational status in both primary tumor and corre-
sponding metastases and TKI responsiveness.
Moreover, several previous studies assessing the KRAS
mutation status in primary tumors have suggested that
KRAS mutation is uncommon in squamous cell
carcinomas. Our data showed that the KRAS mutations
were detected in the primary tumor of one adenocarci-
noma and also in six metastatic tumors (five squamous
cell carcinomas and one adenocacinoma), consistent
with those previous reports. This result also suggests
that the KRAS mutations might play an important role
during metastases of NSCLC, especially squamous cell
carcinomas.
Neoadjuvant or presurgical therapy is a novel thera-
peutic strategy that is now being investigated in the
treatment of NSCLC. In part predicated on the success
of this paradigm in other malignancies (such as colorec-
tal, pancreatic, and urothelial cancers), presurgical ther-
apy has the potential to provide real-time clinical
feedback on the responsiveness of the patient’so v e r a l l
tumor burden to a given systemic therapy before com-
mitting the patient to what could be a highly morbid
surgical procedure. Other potential benefits of this
approach include local tumor down-staging, which may
make subsequent surgical extirpation less morbid. In the
case of locally advanced NSCLC, presurgical therapy
may eliminate micrometastatic disease at its earliest
stage, thus diminishing the risk of metastatic progres-
sion postoperatively. With the development and imple-
mentation of molecular targeted therapies that can
meaningfully affect the biology of both primary tumors
and metastases, the practice has largely been extended
into the era of targeted therapy. In our study among five
patients with EGFR TKI-sensitive mutations in mediast-
inal lymph node metastases, there were four patients
who showed tumor regression in response to EGFR TKI
and underwent surgery. These responses included
dimension reductions in both primary tumors and med-
iastinal lymph nodes, suggesting tumor down-staging.
Therefore, it is intriguing to consider the utilization of
targeted therapies as an adjunct to make the “unresect-
able” become resectable. Neoadjuvant target therapy for
NSCLC could potentially become a new treatment
option for locally advanced and metastatic disease. On
the other hand, we should not ignore the possibility that
gene mutation status of primary tumors is different
from that of their metastases when neoadjuvant target
therapy is considered. If discordance between primary
tumors and metastases is not evaluated before therapy,
the patients may not benefit from the targeted therapies.
Taken together, we propose that biopsies of both pri-
mary tumors and metastatic tumors of patients with
advanced NSCLC, though difficult to obtain, should be
pursued to ascertain the mutation status of key genes.
This will allow clinicians to better understand gene
mutation status and the biology of patient tumors, so
that better treatment options can be selected based on
tumor responsiveness to those available targeted thera-
pies such as EGFR TKI.
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In summary, the substantial discordance of KRAS and
EGFR mutation status between primary tumors and
metastatic tumors may have therapeutic implications for
EGFR-targeted therapy strategy. For NSCLC patients
with metastases, determining the KRAS and EGFR
mutation status in both primary and metastatic tumors
may be critical for making meaningful decisions regard-
ing the appropriate use of targeted therapies.
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